(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Paul Feig loves a plot twist. Why not reboot 'Die Hard' starring a woman? - 2Best Getaway destination: Ocean side, Mountain, or City
- 3Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- 4All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- 5Clovis Unified students spend spring break traveling through China
- Nigeria warns its citizens in South Africa to be cautious after march turns violent
- Explainer-What has happened to the damaged spacecraft at China's space station?
- Syrian army says recent drone attacks targeted its bases near Iraq, most shot down
- NAFFIC, AWARE claim first China-EU DPP for textiles
- Police break up illegal chicken slaughter in Germany
- AbbVie plans to build out its presence in obesity market
- Cyprus: War-related tourism concerns and climate change efforts
- Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
- Elite Execution Wall televisions for Film Darlings
